Piracetam has a strong selective action, without analgesic, sedative, or psychostimulant effects, and does not cause adverse reactions typical of psychotropic drugs. It is also non-addictive. Piracetam improves cerebral metabolism and is indicated for acute and chronic cerebrovascular diseases, traumatic brain injury, various toxic encephalopathies, and other causes of memory impairment and mild to moderate cognitive dysfunction. It is also used for developmental delays in children's intelligence. Fokam Pharmaceutical's piracetam has a CDE registration status of "A", with a production license date of March 22, 2022, and is currently on the market for sale.